Download PDF
Thromb Haemost 1992; 68(03): 306-309
DOI: 10.1055/s-0038-1656370
Original Article
Schattauer GmbH Stuttgart

Effect of DDAVP on Endotoxin-Induced Intravascular Coagulation in Rabbits

M J Paloma
The Hematology Service, University Clinic, Faculty of Medicine, University of Navarra, Pamplona, Spain
,
J A Páramo
The Hematology Service, University Clinic, Faculty of Medicine, University of Navarra, Pamplona, Spain
,
E Rocha
The Hematology Service, University Clinic, Faculty of Medicine, University of Navarra, Pamplona, Spain
› Author Affiliations
Further Information

Publication History

Received 18 September 1991

Accepted after revision 09 April 1992

Publication Date:
04 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

We have evaluated the effect of l-Deamino-8D-arginine vasopressin (DDAVP) on an experimental model of intravascular coagulation (DIC) induced in rabbits by injection of 20 µg kg–1 h–1 during 6 h of E. coli lipopolysaccharide. DDAVP significantly ameliorated the platelet drop and fibrinogen decrease (p <0.01) induced by endotoxin in control animals. A significant reduction in factor XII consumption (p <0.01) and a decrease in the generation of endotoxin induced PAI-1 activity in rabbits circulation was also observed (p <0.005). Moreover, fibrin deposition in kidneys of rabbits receiving DDAVP was significantly reduced as compared to control animals. Finally, the mortality rate in the control group was significantly higher than in DDAVP-treated rabbits (p <0.01). The hemostatic changes induced by DDAVP correlated with lower fibrin deposition and reduction in mortality rates.

 

  • References

  • 1 Morrison DC, Ulevitch RJ. The effects of bacterial endotoxins on host mediation systems. A review. Am J Pathol 1978; 93: 526-617
    PubMedGoogle Scholar
  • 2 Morrison DC, Cochrane CG. Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins). J Exp Med 1974; 140: 797-811
    CrossrefPubMedGoogle Scholar
  • 3 Osterud B, Bjorklid E. Human factor VII associated with endotoxin stimulated monocytes in whole blood. Biochem Biophys Res Commun 1982; 108: 620-626
    CrossrefPubMedGoogle Scholar
  • 4 Warr TA, Rao LVM, Rapaport SI. Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: Effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood 1990; 75: 1481-1489
    PubMedGoogle Scholar
  • 5 Muller-Berghaus G, Schneberger R. Hageman factor activation in the generalized Shwartz reaction induced by endotoxin. Br J Haematol 1971; 21: 513-527
    CrossrefPubMedGoogle Scholar
  • 6 Colucci M, Páramo JA, Collen D. Generation in plasma of a fast acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985; 75: 818-824
    CrossrefPubMedGoogle Scholar
  • 7 Páramo JA, Colucci M, Collen D, Van de Werf F. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J 1985; 291: 573-574
    CrossrefPubMedGoogle Scholar
  • 8 Páramo JA, Fernández FJ, Rocha E. Plasminogen activator inhibitor activity in bacterial infection. Thromb Haemostas 1988; 59: 451-454
    PubMedGoogle Scholar
  • 9 Rocha E, Páramo JA, Fernández FJ, Cuesta B, Hernández M, Paloma MJ, Rifón J. Clotting activation and impairment of fibrinolysis in malignancy. Thromb Res 1989; 54: 699-707
    CrossrefPubMedGoogle Scholar
  • 10 Páramo JA, Pérez JL, Serrano M, Rocha E. Types 1 and 2 plasminogen activator inhibitor and tumor necrosis factor alpha in patients with sepsis. Thromb Haemostas 1990; 64: 3-6
    PubMedGoogle Scholar
  • 11 Gómez C, Páramo JA, Colucci M, Rocha E. Effect of heparin and/or antithrombin III on the generation of endotoxin-induced plasminogen activator inhibitor. Thromb Haemostas 1989; 62: 694-698
    PubMedGoogle Scholar
  • 12 Richardson DW, Robinson AG. Desmopressin. Ann Intern Med 1985; 103: 228-239
    CrossrefPubMedGoogle Scholar
  • 13 Kobrinsky NL, Israel ED, Gerrard JM. et al Shortening of the bleeding time by l-deamino-8-D-arginine vasopressin in various bleeding disorders. Lancet 1984; 1: 1145-1148
    PubMedGoogle Scholar
  • 14 Escolar G, Cases A, Monteagudo J. et al Uremic plasma after infusion of desmopressin (DDAVP) improves the interaction of normal platelets with vessel subendothelium. J Lab Clin Med 1989; 114: 36-42
    PubMedGoogle Scholar
  • 15 Ruggeri ZM, Manucci PM, Lombardi R, Federici AB, Zimmerman TS. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand’s diseases subtypes. Blood 1982; 59: 1272-1278
    PubMedGoogle Scholar
  • 16 Vicente V, Alberca I, López Borrasca A. Response of factor VIII/von Willebrand factor to intranasal DDAVP in healthy subjects and mild haemophiliacs (with observations in patients with combined deficiency of factors V and VIII). Thromb Haemostas 1982; 48: 91-93
    PubMedGoogle Scholar
  • 17 Grant MB, Guay C, Tottenberg R. Desmopressin stimulates parallel norepinephrine and tissue plasminogen activator release in normal subjects and patients with diabetes mellitus. Thromb Haemostas 1988; 59: 269-272
    PubMedGoogle Scholar
  • 18 Hasset MA, Krishnamurti C, Barr CF, Alving BM. The rabbit as a model for studies of fibrinolysis. Thromb Res 1986; 43: 313-318
    CrossrefPubMedGoogle Scholar
  • 19 Krishnamurti C, Barr CF, Hasset MA, Young GD, Alving BM. Plasminogen activator inhibitor: a regulator of ancrod-induced fibrin deposition in rabbits. Blood 1987; 69: 798-803
    PubMedGoogle Scholar
  • 20 Verheijen JH, Mullaart E, Chang GTG, Kluft C, Winjgaards GA. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemostas 1982; 48: 266-269
    PubMedGoogle Scholar
  • 21 Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320: 1165-1172
    CrossrefPubMedGoogle Scholar
  • 22 Van der Poll T, Levi M, Buller HR. et al Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 1991; 174: 729-732
    CrossrefPubMedGoogle Scholar
  • 23 Mannucci PM, Remuzzi G, Püsineri F. et al Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983; 308: 08-12
    CrossrefPubMedGoogle Scholar
  • 24 Mannucci PM, Vicente V, Vianello L. et al Controlled trial of desmopressin (DDAVP) in liver cirrhosis and other conditions associated with prolonged bleeding time. Blood 1986; 67: 1148-1153
    PubMedGoogle Scholar
  • 25 Mannucci PM. Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood 1988; 72: 1449-1455
    PubMedGoogle Scholar
  • 26 Salzman EW, Weinstein MJ, Weintraub RM. et al Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. N Engl J Med 1986; 314: 1402-1406
    CrossrefPubMedGoogle Scholar
  • 27 Rocha E, Llorens R, Páramo JA, Arcas R, Cuesta B, Martin Trenor A. Does desmopressin acetate reduce blood loss after surgery in patients on cardiopulomary bypass?. Circulation 1988; 77: 1319-1323
    CrossrefPubMedGoogle Scholar
  • 28 Levi M, Biemond B, Brandjes D, Hack CE, ten Cate JW. Fibrinolytic response upon DDAVP in factor XII deficient patients. Br J Haematol 1990; 76 (Suppl 1): 11 (Abstr)
    PubMedGoogle Scholar
  • 29 Vicente V, Alberca I, Calles I, López Borrasca A. Effect of DDAVP on contact phase of blood coagulation. Br J Haematol 1984; 56: 679-680
    CrossrefPubMedGoogle Scholar
  • 30 Smith D, Gilbert M, Owen WG. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 1985; 66: 835-839
    PubMedGoogle Scholar